Introduction {#S0001}
============

Gastric cancer (GC) is an important cancer worldwide as it is the fifth most frequently diagnosed cancer, with more than 1,000,000 new cases diagnosed in 2018.[@CIT0001] Moreover, GC is one of the most common malignancies in China.[@CIT0002] With the rapid aging of the global population, the number of elderly patients with locally advanced GC is also increasing in China, with GC being the most common malignancy in the Chinese elderly population.[@CIT0003] Gastrectomy with precise lymph node dissection remains the main treatment modality for GC,[@CIT0004] but studies have shown a high incidence of postoperative complications (PCs) in the elderly at up to 18--32%.[@CIT0005] PCs are the primary cause of severe economic and social burden among elderly GC patients. Thus, timely intervention is crucial in elderly patients as this may decrease PCs and mortality.[@CIT0006]

Hyponatremia and hypocalcemia are common in surgery,[@CIT0007] and it occurs in as high as 47% of hospitalized cancer patients.[@CIT0008] The prognostic significance of hyponatremia and hypocalcemia is well described for several tumor types, such as hypercalcemia for breast and kidney cancer and hyponatremia for small cell lung cancer,[@CIT0009] but has not been well studied in GC.

Serum sodium and calcium levels can be easily determined via routine plasma electrolyte tests. Hyponatremia (i.e., serum sodium level at lower limit of normal (LLN) \<135 mEq/l)[@CIT0010] was considered to be an indicator of severity and prognosis of the underlying disease in various medical conditions, including liver cirrhosis[@CIT0011] and congestive heart failure.[@CIT0012] Further, hyponatremia can develop as a side effect of drug therapy.[@CIT0013] Meanwhile, hypocalcemia (i.e., serum calcium level \<LLN-8.0 mg/dL or \<LLN-2.0 mmol/L; ionized calcium \<LLN-1.0 mmol/L)[@CIT0010] often develops gradually and has nonspecific symptoms. Further, it may resemble the symptoms of the underlying malignancy and its treatment.[@CIT0014]

Hyponatremia and hypercalcemia are the most common cancer-related electrolyte disorders. However, the relationship between GC and hyponatremia or hypocalcemia remains unclear, and thus their management in cancer patients is yet to be established. Because elderly patients usually have poor oral intake, vomiting, diarrhea, and chronic blood loss, they may be more susceptible to hyponatremia or hypocalcemia. Thus, this study aimed to comprehensively evaluate the postoperative prognostic impact of hyponatremia or hypocalcemia in GC patients by age.

Materials And Methods {#S0002}
=====================

Study Design And Subjects {#S0002-S2001}
-------------------------

This retrospective study was performed using data of GC patients who underwent radical gastrectomy at the Gastroenterology Department of the Second Affiliated Hospital of Wenzhou Medical University between June 2009 and February 2018.

The inclusion criteria were: i) gastric adenocarcinoma confirmed via preoperative gastroscopy and pathological examination and ii) scheduled for curative gastrectomy. The exclusion criteria were: i) radiological assessment in another hospital; ii) history of palliative resection; iii) history of emergency surgery for preoperative gastrointestinal bleeding; iv) history of immune system disease, uremia, and severe preoperative kidney function damage; v) and difference in pre- and postoperative diagnosis.

Data on 1) clinicodemographic characteristics including sex, age, electrolyte concentration, body mass index (BMI), preoperative comorbidities, Charlson score, albumin concentration, hemoglobin concentration, histological type, tumor location, tumor node-metastasis (TNM) stage, and tumor size; 2) operative characteristics including laparoscopic surgery (surgeries were mainly performed by laparoscopy except for reconstruction of the digestive tract), lymph node dissection, and type of resection and reconstruction; and 3) postoperative outcomes, including PCs and postoperative survival time were collected from medical records. The patients were divided into two groups by age at a cut-off of 60 years based on the report of the United Nations World Health Organization[@CIT0015] Particularly, the young and the elderly group comprised those aged \<60 years and ≥60 years, respectively. Two experienced researchers graded PCs that occurred within 30 days after operation using the Clavien-Dindo classification.[@CIT0016],[@CIT0017] The study was approved by the Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University; all participants provided written informed consent before participating in the study.

Diagnosis Of Electrolyte Abnormalities {#S0002-S2002}
--------------------------------------

Hyponatremia and hypocalcemia were defined according to the Common Terminology Criteria of Adverse Events, version 4.03.[@CIT0010] Hyponatremia and hypocalcemia were acquired as a time-varying covariate because they could resolve and then recur.[@CIT0018] Therefore, the blood calcium and blood sodium concentrations determined after admission were used for the assessment of hyponatremia and hypocalcemia.

Statistical Analysis {#S0002-S2003}
--------------------

A Kolmogorov--Smirnov test was conducted to evaluate the equality of constant parameter distribution. Normal distribution data are expressed as mean ± SD deviations, while non-normal distribution data are expressed as mean and interquartile ranges (IQR). In univariate analysis, the independent *t*-test and Mann--Whitney *U*-test were used to analyze intergroup differences in continuous variables, and the chi-square test and Fisher's exact test were applied for categorical variables. Overall survival (OS) was defined as the time between the date of diagnosis and death or the date of last known follow-up. The Kaplan--Meier method and log rank test were used to estimate and compare survival based on specific factors. The Cox proportional hazard model was used to assess the risk ratio in univariate and multivariate analyses. All P-values were bilateral, and P\<0.05 was considered statistically significant. All statistical analyses were analyzed using SPSS software (version 23.0; SPSS Inc., Chicago, IL, USA).

Results {#S0003}
=======

Patient Characteristics {#S0003-S2001}
-----------------------

Of the 869 patients initially identified, we excluded 27 patients whose serum calcium and sodium levels were not measured (n=8), those who had metastases to other sites and underwent palliative surgery (n=8), who were previously diagnosed with severe preoperative kidney function damage (n=2), and whose postoperative diagnosis was different from the preoperative diagnosis (n=9). Finally, the cohort comprised 842 patients who were accordingly grouped based on their sodium and calcium levels as the hyponatremia group (n=100 (11.9%)) and non-hyponatremia group (n=742 (88.1%)), and the hypocalcemia group (n=176 (20.9%)) and non-hypocalcemia group (n=666 (79.1%)).

The patient characteristics are shown in [Table 1](#T0001){ref-type="table"}. Majority of patients were men (n=627, 74.5%), and the mean age in the overall cohort was 64.0 (IQR=56.0--72.0) years, indicating that majority were elderly. The median postoperative hospital stay was 16.1 (IQR=13.2--21.1) days, and the median hospitalization expense was ¥34,718.4 (IQR=¥22,003.8--50,495.2). The median preoperative hemoglobin and preoperative albumin levels were 124.0 (IQR=105.0--136.0) g/l and 36.1 (IQR=32.7--38.7) g/l, respectively. The median postoperative survival time was 82.2 months (IQR=78.2--86.3) days.Table 1Clinical Characteristics According To Electrolyte AbnormalitiesFactorsTotal 842(%)Hyponatremia 100(%)Non-Hyponatremia 742(%)*P*Hypocalcemia 176(%)Non-Hypocalcemia 666(%)*P*Age, y64.0(56.0--72.0)65.0(57.2--73.7)64.0(56.0--72.0)73.0(67.0--78.0)69.0(60.0--77.0)Gender0.1100.568 Male627(74.5)81(81.0)546(73.6)134(76.1)493(74.0) Female215(25.5)19(19.0)196(26.4)42(23.9)173(26.0)Preoperative hemoglobin, g/L124.0(105.0--136.0)119.0(103.2--133.7)125.0(106.0--136.0)121.0(100.0--131.0)124.0(102.0--136.5)Preoperative albumin, g/L36.1(32.7--38.7)35.5(32.5--38.2)36.2(32.9--38.8)34.7(31.8--32.7)35.4(32.4--38.0)BMI, kg/m20.048\*0.435 \<23.9650(77.2)85(85.0)565(76.1)132(75.0)518(77.8) ≥23.9192(22.8)15(15.0)177(23.9)44(25.0)148(22.2)Diabetes0.7640.660 Yes69(8.2)9(9.0)60(8.1)13(7.4)56(8.4) No773(91.8)91(91.0)682(91.9)163(92.6)610(91.6)Hypertension0.4950.736 No616(73.2)76(76.0)540(72.8)127(72.2)489(73.4) Yes226(26.8)24(24.0)202(17.2)49(27.8)178(26.6)Albumin, g/L0.4820.068 \<3084(10.0)8(8.0)76(10.2)24(13.6)60(9.0) ≥30758(90.0)92(92.0)666(89.8)152(86.4)606(91.0)Node status0.0660.115 N0362(43.0)33(33.0)329(44.3)63(35.8)299(44.9) N1111(13.2)15(15.0)96(12.9)22(12.5)89(13.4) N2148(17.6)16(16.0)132(17.8)37(21.0)111(16.7) N3221(26.2)36(36.0)185(25.0)54(30.7)167(25.0)Charlson score0.175\<0.001\* 0(0)313(37.2)33(33.0)280(37.7)46(26.1)267(40.1) 1(1--3)375(44.5)42(42.0)333(44.9)79(44.9)296(44.4) 2(4--6)154(18.3)25(25.0)128(17.4)51(29.0)103(15.5)Tumor size0.024\*\<0.001\* ≤4.75595(70.7)61(61.0)534(72.0)101(57.4)494(74.2) \>4.75247(29.3)39(39.0)208(28.0)75(42.6)172(25.8)T stage0.0630.020\* Tis/T1166(19.7)14(14.0)152(20.5)21(11.9)145(21.8) T2183(21.7)15(15.0)168(22.6)40(22.7)143(21.5) T3165(19.6)23(23.0)142(19.1)34(19.3)131(19.7) T4328(39.0)48(48.0)280(37.8)81(46.1)247(37.0)Preoperative anemia0.901\<0.001\* No769(91.3)91(91.0)678(91.4)139(79.0)630(94.6) Yes73(8.7)9(9.0)64(8.6)37(21.0)36(5.4)Preoperative bleeding0.5740.003\* No808(96.0)97(97.0)711(95.8)162(92.0)646(97.0) Yes34(4.0)3(3.0)31(4.2)14(8.0)20(3.0)Preoperative obstruction0.003\*\<0.001\* No811(96.3)91(91.0)720(97.0)161(91.5)650(97.6) Yes31(3.7)9(9.0)22(3.0)15(8.5)16(2.4)Postoperative complication0.004\*\<0.001\* No636(75.5)64(64.0)572(77.1)115(65.3)521(78.2) Yes206(24.5)36(36.0)170(22.9)61(34.7)145(21.8)Postoperative hospital stay, days16.1(13.2--21.1)16.0(13.9--21.1)16.0(13.1--21.0)17.0(14.0--21.1)17.0(14.0--21.1)Hospitalization expense, ¥34,718.4(22,003.8--50,495.2)59,037.1(47,429.4--69,693.5)57,947.3(47,717.4--71,369.5)65,732.7(51,124.7--79,896.1)63,673.0(51,069.0--79,478.8)[^2][^3]

Correlation Between Clinicopathologic Characteristics And Hyponatremia {#S0003-S2002}
----------------------------------------------------------------------

BMI (P=0.048), tumor size (P=0.024), preoperative obstruction (P=0.003), and PC (P=0.004) were significantly correlated with hyponatremia ([Table 1](#T0001){ref-type="table"}). Meanwhile, there was no significant association between hyponatremia and sex, Charlson score, diabetes, T stage, hypertension, preoperative anemia, preoperative bleeding, or node status.

Correlation between clinicopathologic characteristics and hypocalcemia {#S0003-S2003}
----------------------------------------------------------------------

Charlson score (P\<0.001), tumor size (P\<0.001), T stage (P=0.020), preoperative anemia (P\<0.001), preoperative bleeding (P=0.003), preoperative obstruction (P\<0.001), and PC (P\<0.001) were significantly correlated with hypocalcemia. Meanwhile, there was no significant association between hypocalcemia and sex, BMI, T stage, diabetes, hypertension, or node status.

Univariate And Multivariate Analysis Of Factors Associated With Postoperative Complications {#S0003-S2004}
-------------------------------------------------------------------------------------------

Patients with hyponatremia or hypocalcemia had higher risk of PCs ([Figure 1](#F0001){ref-type="fig"}). Univariate analysis showed significant correlations between PCs and age (P\<0.001), diabetes (P=0.037), Charlson score (P=0.003), hyponatremia (P=0.004), hypocalcemia (P\<0.001), TNM stage (P=0.001), T stage (P=0.003), total gastrectomy (P≤0.001), open surgery (P=0.013), and reconstruction methods (P=0.001) ([Table 2](#T0002){ref-type="table"}). Meanwhile, only age (P=0.008), hyponatremia (P=0.039), and hypocalcemia (P=0.023) remained to be independent risk factors for PCs in multivariate logistic regression analysis ([Table 2](#T0002){ref-type="table"}).Table 2Univariate Analysis And Multivariate Analysis Of The Risk Of Postoperative ComplicationFactorsNon-PC Group 636(%)PC Group 206 (%)Univariate AnalysisMultivariate Analysis*PP*Gender0.532 Male477(75.0)150(72.8) Female159(25.0)56(17.2)Age, y\<0.001\*0.008\* \<60262(41.2)57(27.7) ≥60374(58.8)149(72.3)BMI, kg/m20.337 \<23.9496(78.0)154(74.8) ≥23.9140(22.0)52(25.2)Diabetes0.037\* No591(92.9)182(88.3) Yes45(7.1)24(11.7)Hypertension0.624 No468(73.6)148(71.8) Yes168(26.4)58(18.2)Preoperative anemia0.143 No586(92.1)183(88.8) Yes50(7.9)23(11.2)Preoperative bleeding0.493 No612(96.2)196(95.1) Yes24(3.8)10(4.9)Preoperative obstruction0.860 No613(96.4)198(96.1) Yes23(3.6)8(3.9)Charlson score0.003\* 0(0)242(38.1)71(34.5) 1(1--3)294(46.2)81(39.3) 2(4--6)100(15.7)54(26.2)Histologic type0.091 Signet-ring cell carcinoma81(12.7)17(8.3) Differentiated540(84.9)187(90.8) Undifferentiated15(2.4)2(0.9)Hyponatremia0.004\*0.039\* No572(89.9)170(82.5) Yes64(10.1)36(17.5)Hypocalcemia\<0.001\*0.023\* No\
 Yes521(81.9)\
115(18.1)145(70.4)\
61(29.6)Albumin, g/L0.904 ≥30573(90.1)185(89.8) \<3063(9.9)21(10.2)Hemoglobin, g/L0.436 ≥100510(80.2)160(77.7) \<100126(19.8)46(22.3)TNM0.001\* 0/I218(34.3)49(23.8) II103(17.0)25(12.1) III315(48.7)132(64.1)Node status0.059 N0290(45.6)72(35.0) N181(12.7)30(14.6) N2108(17.0)40(19.4) N3157(24.7)64(31.1)T stage0.003\* T1141(22.2)25(12.1) T2141(22.2)42(20.4) T3125(19.7)40(19.4) T4229(35.9)99(48.1)Tumor location0.165 Cardia112(17.6)43(20.9) Corpus141(22.2)52(25.2) Pylorus380(59.7)108(52.4) Total3(0.5)3(1.5)Tumor size0.092 ≤4.75459(72.2)136(66.0) \>4.75177(17.8)70(34.0)Pathological type0.632 Non-ulcerative509(80.0)168(81.6) Ulcerative127(20.0)38(18.4)Total gastrectomy\<0.001\* No515(81.0)142(68.9) Yes121(19.0)64(31.1)Surgical method0.013\* Open560(88.1)194(94.2) Laparoscopic76(11.9)12(15.8)Combined operation0.061 No581(91.4)179(87.0) Yes55(8.6)27(13.0)Reconstruction methods0.001\* Billroth I370(58.2)93(45.1) Billroth II108(17.0)35(17.0) Roux-en-Y158(24.8)78(37.9)[^4][^5] Figure 1Kaplan--Meier curve for overall survival (OS) in patients with hyponatremia or hypocalcemia and those without.

Univariate And Multivariate Analysis Of Factors Associated With Postoperative Complications In Young Patients {#S0003-S2005}
-------------------------------------------------------------------------------------------------------------

The young and the elderly groups comprised 319 (37.9%) and 523 (82.1%) patients, respectively. In total, 52 (16.3%) patients in the young group developed PCs. Univariate analysis showed significant correlations between PCs and Charlson score (P=0.001), pathologic type (P=0.033), and open surgery (P=0.026). Meanwhile, in multivariate logistic regression analysis, pathologic type was the only independent risk factor for PCs. Hyponatremia or hypocalcemia cannot predict PCs in young GC patients.

Univariate And Multivariate Analysis Of Factors Associated With Postoperative Complications In Elderly Patients {#S0003-S2006}
---------------------------------------------------------------------------------------------------------------

In the elderly group, 154 (29.4%) patients developed PCs. In the univariate analysis, there were significant correlations between PCs and diabetes (P=0.050), hyponatremia (P=0.001), hypocalcemia (P=0.003), TNM stage (P=0.018), anastomotic method (P=0.005), and total gastrectomy (P=0.001). In multivariate logistic regression analysis, there were significant correlations between PCs and diabetes (P=0.048), hyponatremia (P\<0.001), and hypocalcemia (P=0.003) ([Table 3](#T0003){ref-type="table"}).Table 3Univariate Analysis And Multivariate Analysis Of The Risk Of Postoperative Complication In Young Patients And Elderly PatientsFactorsYoung Patients (\<60y)Elderly patients (≥60y)Non-PC Group 242(%)PC Group 52(%)Univariate pMultivariate pNon-PC Group 394(%)PC Group 154(%)Univariate pMultivariate pGender0.8830.192 Male165(68.2)36(69.2)312(79.2)114(74.0) Female77(31.8)16(30.8)82(20.8)40(26.0)BMI (kg/m2)0.0830.995 \<23.9194(80.2)36(69.2)302(76.6)118(76.6) ≥23.948(19.8)16(30.8)92(23.4)36(23.4)Charison score0.001\*0.150 0(0)122(50.4)31(59.6)120(30.5)40(26.0) 1(1--3)98(40.5)9(17.3)196(49.7)72(46.8) 2(4--6)22(9.1)12(23.1)78(19.8)42(27.2)Preoperative anemia0.2470.421 No229(94.6)47(90.4)357(90.6)136(88.3) Yes13(5.4)5(9.6)37(9.4)18(11.7)Preoperative bleeding\
 No\
 Yes\
234(96.7)\
8(3.3)\
49(94.2)\
3(5.8)0.396\
378(95.9)\
16(4.1)\
147(95.5)\
7(4.5)0.799Preoperative obstruction\
 No\
 Yes\
234(96.7)\
8(3.3)\
51(98.1)\
1(1.9)0.599\
379(96.2)\
15(3.8)\
147(95.5)\
7(4.5)0.692Hypertension\
 No\
 Yes\
208(86.0)\
34(14.0)\
44(84.6)\
8(15.4)0.803\
260(66.0)\
134(34.0)\
104(67.5)\
50(32.5)0.731Diabetes\
 No\
 Yes\
229(94.6)\
13(5.4)\
49(94.2)\
3(5.8)0.909\
362(91.9)\
32(8.1)\
133(86.4)\
21(13.6)0.050\*0.048\*Hyponatremia\
 No\
 Yes\
215(88.8)\
27(11.2)\
48(92.3)\
4(7.7)0.460\
357(90.6)\
37(9.4)\
122(79.2)\
32(20.8)0.001\*0.001\*Hypocalcemia\
 No\
 Yes\
209(86.4)\
33(13.6)\
42(80.8)\
10(19.2)0.300\
312(79.2)\
82(20.8)\
103(66.9)\
51(33.1)0.0030.038\*Albumin, g/L\
 ≥100\
 \<100\
225(93.0)\
17(7.0)\
49(94.2)\
3(5.8)0.744\
348(88.3)\
46(11.7)\
136(88.3)\
18(11.7)0.997Hemoglobin, g/L\
 ≥100\
 \<100\
207(85.5)\
35(14.5)\
43(82.7)\
9(17.3)0.602\
303(76.9)\
91(23.1)\
117(76.0)\
37(24.0)0.817Tumor size0.0720.470 ≤4.75183(75.6)33(63.5)276(70.1)103(66.9) \>4.7559(24.4)19(26.5)118(29.9)51(33.1)Histologic type\
 Signet-ring cell carcinoma\
40(16.5)\
7(13.5)0.609\
41(10.4)\
10(6.5)0.170 Differentiated199(82.2)45(86.5)341(86.5)142(92.2) Undifferentiated3(1.3)0(0.0)12(3.1)2(1.3)Pathologic type0.033\*0.0380.552 Ulcerative type193(79.8)48(92.3)316(80.2)120(77.9) Non-ulcerative type49(20.2)4(7.7)78(19.8)34(22.1)TNM stage0.0620.018\* 0/I89(36.8)11(21.2)129(32.7)38(24.7) II36(14.9)7(13.5)67(17.0)18(11.7) III117(48.3)34(65.3)198(50.3)98(63.6)N stage\
 N0\
 N1\
 N2\
 N3\
114(47.1)\
30(12.4)\
43(17.8)\
55(22.7)\
18(34.6)\
6(11.5)\
8(15.4)\
20(38.5)0.121\
176(44.7)\
51(12.9)\
65(16.5)\
102(25.9)\
54(35.1)\
24(15.6)\
32(20.8)\
44(28.5)0.217T stage\
 Tis/1\
 T2\
 T3\
 T4\
58(24.0)\
50(20.7)\
46(19.0)\
88(36.3)\
5(9.6)\
10(19.2)\
10(19.2)\
26(50)0.162\
83(21.1)\
91(23.1)\
79(20.1)\
141(35.7)\
19(12.3)\
32(20.8)\
30(19.5)\
73(47.4)0.034\*Tumor location0.1560.246 Cardia29(12.0)11(21.2)83(21.1)32(20.8) Corpus55(22.7)8(15.4)86(21.8)44(28.6) Pylorus157(64.9)32(61.5)223(56.6)76(49.4) Total1(0.4)1(1.9)2(0.5)2(1.2)Anastomotic method0.2840.005\* Billroth I146(60.3)26(50)224(56.9)67(43.5) Billroth II41(16.9)9(17.3)67(17.0)26(16.9) Roux-en-y55(22.7)17(32.7)103(26.1)61(39.6)Total gastrectomy\
 No\
 Yes\
199(82.2)\
43(17.8)\
39(75.0)\
13(25.0)0.228\
316(80.2)\
78(19.8)\
103(66.9)\
51(33.1)0.001\*Combined operation0.4450.142 No226(93.4)47(90.4)355(85.0)132(85.7) Yes16(6.6)5(9.6)39(15.0)22(14.3)Surgical method\
 Open\
 Laparoscopic\
212(87.6)\
30(12.4)\
51(98.1)\
1(1.9)0.026\*\
348(88.3)\
46(11.7)\
143(92.9)\
11(7.1)0.118[^6][^7]

Survival Analysis Of Variables Associated With Hyponatremia Or Hypocalcemia In Young Patients {#S0003-S2007}
---------------------------------------------------------------------------------------------

As shown in [Figure 1](#F0001){ref-type="fig"}, GC patients with hypocalcemia had a poor outcome: the median survival time in patients with hypocalcemia was shorter than in those without hypocalcemia (70.7 months vs, 85.0 months, P=0.005). In the young group, univariate analysis showed that preoperative obstruction (HR, 4.300; 95% CI, 1.310--14.119; P=0.016), readmission (HR, 3.438; 95% CI, 1.052--11.231; P=0.041), larger tumor size (HR, 4.245; 95% CI, 2.213--8.142; P\<0.001), worse histopathological differentiation (HR, 0.424; 95% CI, 0.209--0.862; P=0.018 for differentiated type), higher TNM stage (HR, 19.029; 95% CI, 2.341--154.706; P=0.006 for stage II and HR, 33.578; 95% CI, 4.572--246.582; P=0.001 for stage III), total gastrectomy (HR, 0.418; 95% CI, 0.209--0.832; P=0.013), and anastomotic method (HR, 3.451; 95% CI, 1.438--8.282; P=0.006 for Billroth II and HR, 3.271; 95% CI, 1.576--6.790; P=0.001 for Roux-en-y) were associated with poor OS. On multivariate analysis, readmission (HR, 3.150; 95% CI, 1.638--6.056; P=0.001), higher TNM stage (HR, 0.037; 95% CI, 0.05--0.282; P=0.001 for stage II), tumor location (HR, 0.052; 95% CI, 0.004--0.748; P=0.030 for gastric body and HR, 0.058; 95% CI, 0.004--0.909; P=0.043 for antrum), and anastomotic method (HR, 2.152; 95% CI, 1.176--3.939; P=0.013 for Roux-en-y) were independently associated with worse OS ([Table 4](#T0004){ref-type="table"}). As shown in [Figure 2A](#F0002){ref-type="fig"}， both hyponatremia and hypocalcemia cannot predict the prognosis of young GC patients.Table 4COX Regression Analysis Of The Relationship Between OS And Electrolyte Abnormalities Or Patient Characteristics In Young Patients And Elderly PatientsFactorsYoung Patients (\<60y)Elderly Patients (≥60y)UnivariateMultivariateUnivariateMultivariateHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueGender MaleReferenceReference Female0.802(0.388--1.657)0.5511.069 (0.738--1.548)0.725BMI (kg/m2) \<23.9ReferenceReference ≥23.90.916 (0.418--2.005)0.8260.812 (0.554--1.191)0.287Charison scroe 0ReferenceReference 1--31.411 (0.710--2.803)0.3260.915 (0.637--1.316)0.633 4--61.011 (0.342--2.988)0.9851.198 (0.786--1.827)0.400Hypertension\
 No\
 Yes\
Reference\
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11.445(1.590--82.356)0.015\*[^8][^9] Figure 2Kaplan--Meier curves. (**A**) Kaplan--Meier curve for overall survival (OS) in younger patients with hyponatremia or hypocalcemia and those without. (**B**) Kaplan--Meier curve for overall survival (OS) in elderly patients with hyponatremia or hypocalcemia and those without.

Survival Analysis Of Variables Associated With Hyponatremia Or Hypocalcemia In Elderly Patients {#S0003-S2008}
-----------------------------------------------------------------------------------------------

As shown in [Figure 2B](#F0002){ref-type="fig"}, Interestingly, hypocalcemia predicted poor outcome in the elderly patients: the median survival time in elderly patients with hypocalcemia was shorter than in those without hypocalcemia (55.3 months vs 77.9 months, P\<0.001). In univariate analysis, hypocalcemia (HR, 1.876; 95% CI, 1.358--2.592; P=0.001) was associated with poor OS. Additionally, readmission (HR, 1.783; 95% CI, 1.048--3.034; P=0.033), larger tumor size (HR, 2.100; 95% CI, 1.542--2.860; P\<0.001), worse histopathological differentiation (HR, 4.314; 95% CI, 1.660--11.209; P=0.003 for undifferentiated type), higher TNM stage (HR, 2.486; 95% CI, 1.311--4.713; P=0.005 for stage II and HR, 5.087; 95% CI, 3.064--8.446; P\<0.001 for stage III), total gastrectomy (HR, 0.554; 95% CI, 0.397--0.775; P=0.001), anastomotic method (HR, 2.889; 95% CI, 1.918--4.353; P=0.001 for Billroth II and HR, 2.266; 95% CI, 1.594--3.221; P=0.001 for Roux-en-y), grade \>2 PC (HR, 1.623; 95% CI, 1.176--2.240; P=0.003), multiple surgeries (HR, 1.568; 95% CI, 1.139--2.159; P=0.006), and surgical method (HR, 0.068;, 95% CI, 0.010--0.489; P=0.008 for laparoscopic) were associated with poor OS. No other clinicopathologic factors were statistically correlated to prognosis. On multivariate analysis, hypocalcemia (HR, 0.476; 95% CI, 0.467--0.978; P=0.037), worse histopathological differentiation (HR, 0.181; 95% CI, 0.068--0.483; P=0.001 for differentiated type and HR, 0.277; 95% CI, 0.131--0.586; P=0.001 for undifferentiated type), TNM stage (HR, 0.293; 95% CI, 0.170--0.506; P=0.001 for stage II and HR, 0.583; 95% CI, 0.360--0.943; P\<0.001 for stage III), and surgical method (HR, 11.445; 95% CI, 1.590--82.356; P=0.015 for laparoscopic) were independently associated with worse OS ([Table 4](#T0004){ref-type="table"}).

Discussion {#S0004}
==========

This study retrospectively investigated the impact of preoperative hyponatremia or hypocalcemia on PCs and OS in GC patients by age group. Our results demonstrated that GC patients with hyponatremia or hypocalcemia had a higher risk of developing PCs. PCs not only reduce compliance to succeeding treatment, but also increase medical costs and impair quality of life, and ultimately result in poor prognosis.[@CIT0019],[@CIT0020]

We also found that the incidence of hyponatremia and hypocalcemia was higher in the elderly group. Considering the physiological differences between young patients and elderly patients, we first examined whether hyponatremia or hypocalcemia was correlated with outcome in the young and the elderly patient groups. Interestingly, hyponatremia or hypocalcemia was an independent risk factor for PCs in the elderly group (hyponatremia, P=0.001; hypocalcemia, P=0.003), but it was not significant on univariate analysis in the young group. Moreover, similar to the results of other studies,[@CIT0021]--[@CIT0023] we found that OS was significantly shorter in elderly GC patients with preoperative hypocalcemia or hyponatremia, and hypocalcemia was found to be an independent risk factor of OS in the elderly group (HR=0.676, P=0.037), but not in the young group. This may be explained by the fact that the relationship between chronic illness and certain factors such as malnutrition and immobility make elderly patients particularly vulnerable to hyponatremia or hypocalcemia. Furthermore, the value of hyponatremia or hypocalcemia as a predictor for PCs and OS in elderly patients may be blunted by age and age-related poor physical condition. Additionally, considering the same diagnostic criteria and their better fundamental physical condition, young patients with hyponatremia or hypocalcemia may have better nutritional intake than elderly patients with hyponatremia or hypocalcemia. Although preoperative hyponatremia or hypocalcemia is associated with a poorer prognosis in elderly GC patients, there are still questions as to whether hyponatremia or hypocalcemia is a marker of disease severity[@CIT0024] and if the correction of hyponatremia or hypocalcemia is beneficial for OS.[@CIT0025],[@CIT0026]

Cancer outcomes have improved over the last few decades, but the prognostic impact of hyponatremia or hypocalcemia in cancer remains unclear. A study has suggested that correction of hyponatremia or hypocalcemia improves survival,[@CIT0027] but the mechanisms behind these relationships are still ambiguous and poorly understood. In cancer patients, hyponatremia is usually caused by inadequate antidiuretic hormone (SIADH) secretion by the tumor.[@CIT0028],[@CIT0029] In this case, a hyponatremic state is mainly induced by the ectopic secretion of arginine vasopressin from the tumor tissue.[@CIT0030] Although SIADH may be the cause of hyponatremia, there is little evidence that SIADH is the primary cause for hyponatremia in GC patients. In the present study, whether hyponatremia was related to SIADH could not be assessed; thus, their potential relationship remains to be further clarified. However, there are some possible causes of hyponatremia in patients with gastric cancer. A subset of chemotherapy drugs can cause hyponatremia by affecting the cytotoxicity of the central nervous system. In fact, chemotherapy or radical gastrectomy is usually accompanied by severe stress reaction, which may lead to or aggravate hyponatremia. However, according to current research, the actual mechanism of poor PCs and OS due to hyponatremia is still not very clear. Renal or endocrine dysfunction, cancer cells producing antidiuretic hormone (ADH) and higher than normal levels of ADH in the microenvironment of gastric cancer are reasonable potential explanations.

As for hypocalcemia, one study indicated that impaired renal function and increased renal tubular calcium resorption may cause hypocalcemia. Deterioration of the kidney function itself may be an indication of inflammation. The proinflammatory pathways is mainly regulated by the tumor microenvironment, and this plays an important role in tumor progression. Tumor-induced inflammation may alters endothelial/vascular kidney function, and this leads to reduced calcium reabsorption and diminished renal function.[@CIT0031] However, this needs to be verified. Although our findings suggest that hyponatremia or hypocalcemia is an adverse prognostic factor, it is unclear if hyponatremia or hypocalcemia is the result of multiple pathophysiological effects or an independent biological factor. Additional research is needed to clarify this.

This is the first study to focus on hyponatremia or hypocalcemia in GC patients, and we evaluated elderly patients who have higher risk of PCs and worse clinical outcome than young patients. Findings from another study suggest that correction of sodium and calcium concentration levels in GC patients with severe hyponatremia or hypocalcemia allows for additional treatments and result in significantly better OS.[@CIT0032] Thus, we propose that more attention should be paid to improve the hyponatremic or hypocalcemia status in elderly patients. The urgency and aggressiveness of treatment for elderly patients is predicated on both the serum calcium and serum sodium, and importantly, the manifesting symptoms. Fluid restriction (generally to 500 mL less than the daily urine output) is a common treatment strategy for transient hyponatremia. However, it may be difficult to perform in elderly GC patients.[@CIT0033] Because hydration is an indispensable step in chemotherapy, and fluid-limiting measures can affect nutrient absorption and quality of life. Thus, we recommend a new and physiologically based therapy for elderly GC patients with hyponatremia.

The site of vasopressin action in the distal tubule and may antagonize vasopressin type 2 receptors, leading to water retention.[@CIT0034] In addition, given that the treatment of hypocalcemia in elderly GC patients is aimed to improve serum calcium concentration by treating underlying diseases, particularly by reducing urinary excretion of calcium; promoting calcium absorption in the bone; and, to a lesser extent, increasing intestinal calcium absorption, the blood sodium and blood calcium level should be maintained at stable levels before surgery. Meanwhile, although hyponatremia or hypocalcemia also needs to be treated in young patients and blood sodium and calcium levels should also be stabilized, treatment indications can be lightened.

There are several limitations in this study that should not be overlooked. First, due to technical and conditional restrictions, we only chose to investigate hyponatremia and hypocalcemia, and they were not rated according to their severity. Therefore, we will continue to study the postoperative effects of other types of electrolyte disorders on GC patients and rank them by severity. Second, all the data measured in our study were obtained from the first blood collection after admission, and clinicians tend to correct the hyponatremia or hypocalcemia after its diagnosis. Whether this has an impact on the prognosis still needs to be further studied. Third, bias in population selection may be inevitable due to the single-center design. Therefore, a large-scale multicenter trial is necessary to confirm our findings. Fourth, we only analyzed two age categories at a cutoff of 60 years. The effect of hyponatremia or hypocalcemia in different age groups needs to be further studied. Finally, the follow-up period in the present study is less than 5 years, and long-term follow-up data need to be further acquired.

Conclusions {#S0005}
===========

This is the first retrospective study to identify hyponatremia and hypocalcemia as independent risk factors for PCs and OS in GC patients. Additionally, hyponatremia and hypocalcemia were independent predictors of poor outcomes only in elderly GC patients, and not in young patients. Therefore, greater attention should be paid to hyponatremia or hypocalcemia in elderly GC patients.
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